NCT01015248已完成2 期
Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea19 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 19
- 主要终点
- The primary endpoint of assessment is the event-free-survival (EFS) according to the criteria of the International Workshop to Standardize Response Criteria for NHL and Criteria for evaluation of response in NHL
研究概览
简要总结
The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.
Primary endpoint:
- Event-free-survival (EFS) (failure or death from any cause) for all patients.
Secondary endpoints:
- Complete and partial remission rates for all patients
- Response duration (time to relapse or progression) for responder patients
- Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
- Overall survival for all patients
- Acute and long-term toxicity
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 84 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site (WHO classification)
- •Any stage (Ann Arbor I-IV)
- •The novo disease en any extranodal site. For primary gastric or cutaneous lymphoma, local/specific previous treatment is accepted, just following the below criteria:
- •Cutaneous lymphoma: recurrent lymphoma after local therapy
- •Gastric lymphoma:
- •H. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).
- •H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including patients with: clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication; stable disease with persistent lymphoma at 1 year post H. pylori eradication; relapse (without H. pylori re-infection), after a remission; patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy)
- •No evidence of histologic transformation to a high grade lymphoma
- •Measurable or evaluable disease
- •Age >18 and <85
- •ECOG performance status 0-2
- •Life expectancy of at least 1 year
- •Written informed consent given according to national/local regulations
排除标准
- •Prior chemotherapy or prior immunotherapy with any anti-CD20 monoclonal antibody
- •Prior radiotherapy in the last 6 weeks
- •Corticosteroids during the last 28 days, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
- •Major impairment of renal function (serum creatinine > 2,5 x upper normal) or liver function (ASAT/ALAT <2,5 x upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma involvement.
- •Impairment of bone marrow function (WBC <3.0x109/L, ANC <1.5x109/L, PLT <100x109/L), unless due to lymphoma involvement
- •Evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement
- •Evidence of symptomatic central nervous system (CNS) disease
- •Active HBV and/or HCV infection
- •Known HIV infection
- •Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer
- •Any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule
- •Potential to attend regular visits to the hospital, on an outpatient regimen
- •Hypersensibility to any compound of the study medication.
- •Non appropriate contraceptive method in women of childbearing potential or men
- •Treatment with any drug under research within 30 days previous to start the study medication.
研究组 & 干预措施
Rituximab and Bendamustine
Experimental
干预措施: Rituximab and Bendamustine (Drug)
结局指标
主要结局
The primary endpoint of assessment is the event-free-survival (EFS) according to the criteria of the International Workshop to Standardize Response Criteria for NHL and Criteria for evaluation of response in NHL
时间窗: 2 years follow-up
次要结局
- Include evaluation of the next parameters: Complete and partial remission rates for all patients Response duration for responder patients PFS for all patients Overall survival for all patients Acute and long-term toxicity(2 years follow-up)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
2 期
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's LymphomaIndolent Non-follicularNon-Hodgkin's LymphomaNCT01929265Fondazione Italiana Linfomi - ETS73
进行中（未招募）
1 期
Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaMultiple MyelomaNCT01754402Cristina Gasparetto56
已完成
2 期
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaDiffuse Large B-Cell LymphomaLymphoma, Diffuse Large-CellDiffuse Large-Cell LymphomaLymphomaNCT01234467UNC Lineberger Comprehensive Cancer Center23
终止
1 期
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaMultiple MyelomaNCT01177683Sherif Farag, MB, BS32
终止
2 期
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingLymphatic DiseasesNCT02499627Fondazione Italiana Linfomi - ETS43